BioSpace News Archive

Achilles Therapeutics plc today announced that its Co-founder Charles Swanton, MD, PhD, FRS, FRCP from the Francis Crick Institute & UCL, and Scientific Advisory Board member Christopher Klebanoff from Memorial Sloan Kettering will join John Haanen, MD from the Netherlands Cancer Institute on a Neoantigen Expert Roundtable to discuss the importance of neoantigens as targets in solid tumor cell therapy.

Tarsus Pharmaceuticals, Inc., whose mission is to address unmet patient needs, starting with eye care, through the application of proven science and new technology, announced the appointment of Scott Morrison as Board Member and Audit Committee Chair.

Mustang Bio, Inc. today announced that the first patient has been treated in its multicenter, open-label, non-randomized Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106, Mustang’s first-in-class CD20-targeted, autologous CAR T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHL”) and chronic lymphocytic leukemia (“CLL”).

As the U.S. enters another cold and flu season along with the potential of rising infections from COVID variants, global heart health leader OMRON Healthcare is issuing a national health alert warning of increased risk for those with high blood pressure and calling for regular blood pressure monitoring and active management of hypertension.

Natera, Inc. today announced the publication of a manuscript in Gynecologic Oncology, found here, validating the performance of its personalized molecular residual disease (MRD) test, Signatera, in epithelial ovarian cancer (EOC).

Devonian Health Group Inc. today announced the publication of Thykamine™ positive phase 2 trial in adult patients with mild-to-moderate Atopic Dermatitis (AD) in the peer-reviewed Journal of Drugs in Dermatology (JDD).

Hillstream BioPharma, Inc. today announced that Randy Milby, Founder and Chief Executive Officer will present in-person and host one-on-one meetings with investors at the following conferences.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the initiation of a 3-year longitudinal registry and study to assess the impact of tardive dyskinesia (TD) and real-world treatment patterns and outcomes.

Hyperfine, Inc. announced that it has named medical device industry veteran Maria Sainz as President and Chief Executive Officer of Hyperfine, effective October 24, 2022.

Sensorion is pleased to announce Sensorion’s participation in two scientific conferences in October 2022.